Metformin Hydrochloride Extended Release 1000 mg Tablets: Gliempaflozin Tablet.

Extended Release Metformin Hydrochloride 1000 mg tablets are commonly prescribed for managing type 2 diabetes mellitus. Manufactured by Steris Pharma Pvt Ltd, these tablets effectively regulate blood sugar levels. This article provides an in-depth overview of Extended Release Metformin Hydrochloride, including its formulations, benefits, and combination therapies. 

Metformin Hydrochloride 1000 mg (SR) Sustained Release Tablets are used to manage high blood sugar levels in individuals with type 2 diabetes. In this condition, the insulin produced by the pancreas is unable to effectively transport sugar into the body’s cells for energy use. Metformin can be taken alone, in combination with a sulfonylurea (another oral antidiabetic medication), or with insulin to help lower elevated blood sugar levels and improve how the body processes food for energy.

Many individuals can manage type 2 diabetes through diet and exercise, which remain essential even when taking medication. The effectiveness of metformin depends on balancing the dosage with food intake and physical activity. If changes occur in diet or exercise routines, blood sugar levels should be monitored to prevent them from dropping too low. Your doctor will guide you on how to handle such situations.

Metformin Hydrochloride 1000 mg (SR) is not suitable for individuals with type 1 diabetes, as their condition requires insulin injections due to the pancreas' inability to produce insulin. While some improvement in blood sugar control may be noticeable within 1 to 2 weeks, full benefits typically take 2 to 3 months. This medication is available only with a doctor's prescription. If you have any questions, consult your healthcare provider.

What is Extended Release Metformin Hydrochloride?

Extended Release (ER) Metformin Hydrochloride is designed to release the medication gradually, ensuring prolonged therapeutic effects with fewer side effects. It helps in:

• Enhancing insulin sensitivity

• Reducing hepatic glucose production

• Improving glucose uptake in muscles

Unlike immediate-release formulations, ER Metformin is taken once daily, improving patient compliance and minimizing gastrointestinal discomfort.

Metformin Hydrochloride Tablets IP

Manufactured in compliance with Indian Pharmacopoeia (IP) standards, Metformin Hydrochloride Tablets IP ensure high quality and efficacy. They are prescribed as monotherapy or in combination with other antidiabetic medications to effectively manage blood sugar levels.

Benefits of Metformin Hydrochloride Tablets IP

• Effectively controls high blood sugar levels

• Aids in weight management for diabetic patients

• Lowers the risk of cardiovascular complications

• Minimizes the risk of hypoglycemia when used alone

Metformin Hydrochloride Prolonged Release 1000 mg

Metformin Hydrochloride Prolonged Release 1000 mg is an advanced formulation that provides a steady release of the drug over an extended period. This enhances tolerance and improves effectiveness in managing type 2 diabetes.

Advantages of Prolonged Release Formulations

• Fewer gastrointestinal side effects

• More stable blood glucose levels throughout the day

• Improved adherence due to reduced dosing frequency

Metformin Hydrochloride Prolonged Release Tablets

These tablets ensure a controlled and sustained release of metformin, preventing fluctuations in glucose levels. They are particularly beneficial for patients who experience stomach discomfort with immediate-release formulations.

Combination Therapies

Gliclazide and Metformin Hydrochloride Tablets

This combination brings together two potent antidiabetic agents:

• Metformin Hydrochloride – Lowers hepatic glucose production

• Gliclazide – A sulfonylurea that stimulates insulin release from the pancreas

Benefits of Gliclazide and Metformin Hydrochloride Tablets

• Enhances insulin secretion

• Controls fasting and postprandial blood sugar levels

• Reduces the risk of diabetes-related complications

Glimepiride and Metformin Hydrochloride Tablets

Another effective combination therapy, these tablets help manage type 2 diabetes through dual mechanisms.

Benefits of Glimepiride and Metformin Hydrochloride Tablets

• Glimepiride – Stimulates insulin release and enhances peripheral glucose utilization

• Metformin Hydrochloride – Reduces hepatic glucose production

• Together, they offer superior glycemic control compared to monotherapy

Vildagliptin and Metformin Hydrochloride Tablets

Vildagliptin, a DPP-4 inhibitor, enhances insulin secretion and reduces glucagon levels, complementing the effects of metformin.

Uses of Vildagliptin and Metformin Hydrochloride Tablets

• Enhances glucose-dependent insulin secretion

• Lowers excess glucagon levels in fasting and postprandial states

• Provides better blood sugar control compared to monotherapy

Mechanism of Action:

Metformin Hydrochloride 1000 mg is an oral antidiabetic medication used to manage type 2 diabetes. It works primarily by:

Reducing glucose production in the liver (inhibiting hepatic gluconeogenesis).

Decreasing glucose absorption in the intestines.

Enhancing insulin sensitivity, allowing cells to utilize glucose more effectively.

Unlike some other diabetes medications, metformin does not stimulate insulin secretion, which reduces the risk of hypoglycemia (low blood sugar).

Side Effects:

While generally well-tolerated, metformin may cause some side effects, including:

Common Side Effects: Nausea, vomiting, diarrhea, stomach pain, and loss of appetite, especially in the initial weeks of treatment.

Rare but Serious Side Effects:

Lactic Acidosis: A rare but potentially life-threatening condition that may occur due to excessive lactic acid buildup in the blood. Symptoms include muscle pain, difficulty breathing, dizziness, and extreme fatigue.

Vitamin B12 Deficiency: Long-term use of metformin may lead to reduced B12 absorption, potentially causing anemia or nerve issues.

Contraindications:

Metformin should not be used in individuals with:

Severe kidney disease (eGFR below 30 mL/min/1.73m²).

Severe liver disease or conditions that may predispose to lactic acidosis.

Uncontrolled heart failure or recent heart attack.

Severe infections or dehydration, as these conditions may increase the risk of lactic acidosis.

Alcohol abuse, which can raise the risk of lactic acidosis.

Safety Advice / Warnings:

Take with Food: To minimize gastrointestinal side effects, metformin should be taken with meals.

Kidney Function Monitoring: Regular kidney function tests are necessary, as impaired kidney function can increase the risk of lactic acidosis.

Surgery & Imaging Procedures: Discontinue metformin temporarily before undergoing major surgery or procedures requiring contrast dye, as these may affect kidney function.

Alcohol Consumption: Avoid excessive alcohol intake, as it increases the risk of lactic acidosis.

Pregnancy & Breastfeeding: Consult your doctor before using metformin during pregnancy or while breastfeeding.

Why Choose Metformin Hydrochloride Tablets from Steris Pharma Pvt Ltd?

Steris Pharma Pvt Ltd is renowned for manufacturing high-quality Metformin Hydrochloride Tablets IP and combination therapies. Their formulations are:

• Clinically tested for safety and efficacy

• Produced under strict quality control measures

• Designed for optimal absorption and patient adherence

Why Steris Healthcare Is the Best Option For Metformin Hydrochloride Extended Release 1000 mg Tablet ?

Metformin Hydrochloride Extended Release 1000 mg Tablets are a key component in managing type 2 diabetes. The prolonged-release formulations and combination therapies with Gliclazide, Glimepiride, and Vildagliptin enhance glycemic control while minimizing side effects. With a commitment to high-quality standards, Steris Pharma Pvt Ltd remains a trusted choice for healthcare professionals worldwide.

News Referrences: 

• Mumbai Based Steris Healthcare Announces Expansion Plan IPO Launch: msn.com 
• Steris Healthcare Unveils Rs 50 Crore Expansion Plan, Eyes IPO In FY 2026-27 :  bwhealthcareworld.com
• Mumbai-based Steris Healthcare Pvt Ltd plans to launch IPO in FY 2026-27: indianstartupnews.com
• Steris Healthcare Announces Rs 50 Crore Expansion, IPO Planned For FY 2026-27 : News18.com
• Steris Healthcare Pvt Ltd announces ₹50 crore expansion and IPO plans for FY 2026–27:  expresspharma.com

Steris Healtcare: Our Brand Is List On Trusted News Plateform.

Steris Healthcare, a pharmaceutical company headquartered in Mumbai, has announced a strategic expansion plan worth ₹50 crore. The initiative includes setting up a new manufacturing facility in South India, doubling its current production capacity, and preparing for an Initial Public Offering (IPO) scheduled for the financial year 2026–27.

Having surpassed ₹100 crore in annual sales, Steris Healthcare aims to strengthen its nationwide footprint by expanding into key southern markets such as Kerala, Tamil Nadu, Telangana, and Karnataka. The upcoming manufacturing unit is expected to play a crucial role in enhancing the company's production capabilities and meeting the rising demand from both domestic and international markets.